JPH05336996A - Method for testing cytotoxicity with cultured cell - Google Patents
Method for testing cytotoxicity with cultured cellInfo
- Publication number
- JPH05336996A JPH05336996A JP4153692A JP15369292A JPH05336996A JP H05336996 A JPH05336996 A JP H05336996A JP 4153692 A JP4153692 A JP 4153692A JP 15369292 A JP15369292 A JP 15369292A JP H05336996 A JPH05336996 A JP H05336996A
- Authority
- JP
- Japan
- Prior art keywords
- matrix
- cells
- aqueous solution
- collagen
- specimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、培養細胞を用いて検体
の細胞に対する毒性を試験する細胞毒性試験方法に関
し、特に皮膚組織に対する検体の毒性を試験する細胞毒
性試験方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a cytotoxicity test method for testing the toxicity of a specimen to cells using cultured cells, and more particularly to a cytotoxicity test method for testing the toxicity of a specimen to skin tissue.
【0002】[0002]
【従来の技術】検体の細胞に対する毒性試験としては動
物試験が行なわれているが、動物を使用する毒性試験は
時間と費用がかかり過ぎるばかりでなく、最近動物愛護
の見地より次第に他の試験法が採用されるようになって
いる。その一つとして細胞毒性試験方法がある。この細
胞毒性試験方法としては、51Cr溶出試験、寒天重層
法、ミリポアフィルタ−重層法などの培養細胞を用いる
方法が知られている。51Cr溶出試験法は、予め51Cr
化合物を取り込ませた標識細胞を検体である歯科材料に
暴露すると、障害を受けて51Crが細胞外に放出される
ので、培地中に放出された51Crの放射活性を計測する
ことにより歯科材料の細胞毒性を定量的に検出、評価す
る方法である。寒天重層法は、ペトリ皿上に単層に培養
した細胞の上に、培養液を含む寒天層をのせ、その固化
した寒天層の上に固体や液体の検体を置いて培養を行い
ニュ−トラルレッドで細胞を生きたまま染色し細胞が障
害を受けると色が消えたり溶解するのでその程度を利用
して毒性を評価を行う方法である。ミリポアフィルタ−
重層法は、ミリポアフィルタ−の上に予め培養細胞を単
層培養しておき、このミリポアフィルタ−を細胞層が下
側になるように寒天培地上に置き、フィルタ−上に検体
を置き、所定の時間後に細胞層のコハク酸脱水素酵素活
性を細胞化学的に発色させ、検体による発色阻止域を計
測し毒性を評価する方法である。これらの方法は動物実
験代替法として今後ますます重要になると思われる。2. Description of the Related Art Animal tests have been conducted as toxicity tests on cells of specimens, but the toxicity tests using animals are not only time-consuming and expensive, but recently, other test methods have been gradually adopted from the viewpoint of animal welfare. Has been adopted. One of them is a cytotoxicity test method. As the cytotoxicity test method, methods using cultured cells such as 51 Cr elution test, agar overlay method, Millipore filter-overlay method and the like are known. The 51 Cr elution test method is based on 51 Cr in advance.
When labeled cells that have taken up a compound are exposed to a dental material that is a sample, 51 Cr is released from the cells due to damage, and the dental material is measured by measuring the radioactivity of 51 Cr released in the medium. It is a method for quantitatively detecting and evaluating the cytotoxicity of. In the agar overlay method, agar layer containing the culture solution is placed on the cells cultured in a single layer on a Petri dish, and a solid or liquid sample is placed on the solidified agar layer to perform culture, and then neutralized. It is a method of evaluating toxicity by using the degree of red staining of cells alive and the cells disappearing or dissolving when they are damaged. Millipore filter
In the overlay method, the cultured cells are preliminarily cultivated in a monolayer on the Millipore filter, and the Millipore filter is placed on the agar medium so that the cell layer is on the lower side, and the specimen is placed on the filter. After this time, the succinate dehydrogenase activity of the cell layer is colored cytochemically, and the inhibition zone of color development by the sample is measured to evaluate toxicity. These methods are expected to become increasingly important as alternatives to animal experiments.
【0003】ところで、皮膚に適用する薬剤を検体とし
て、上述のような細胞毒性試験を行い、薬剤の皮膚に対
する毒性を試験することが行なわている。従来の方法
は、細胞を播種した培養シャ−レに、培地中に一定量の
薬剤を添加し、細胞の増殖挙動を検査する方法である。
しかし、皮膚に適用する薬剤は、通常、薬剤含有軟膏あ
るいは被覆材の形態として直接適用するため、細胞毒性
試験としては細胞が三次元的に集合した培養皮膚を用い
た実験系で細胞への影響を調べる方法が望ましく、現在
ベルらの方法が知られている(米国特許第4,835,
102号参照)。この方法はコラ−ゲンマトリックスに
表皮細胞と真皮細胞である線維芽細胞を培養し、皮膚に
近いモデルを作り、検体をこのモデルに乗せ一定時間経
過後の組織切片により観察し評価して検体の毒性を調べ
る方法である。By the way, the above-mentioned cytotoxicity test is carried out using a drug applied to the skin as a sample to test the toxicity of the drug to the skin. The conventional method is a method of inspecting the growth behavior of cells by adding a certain amount of a drug to a culture dish on which cells have been seeded.
However, the drug applied to the skin is usually applied directly in the form of a drug-containing ointment or a covering material, and therefore the effect on cells in an experimental system using cultured skin in which cells are three-dimensionally assembled as a cytotoxicity test. The method of Bell et al. Is currently known (US Pat. No. 4,835,35).
102). In this method, epidermal cells and fibroblasts, which are dermal cells, are cultured in a collagen matrix to make a model close to skin, and the specimen is placed on this model and observed and evaluated by a tissue section after a certain period of time to evaluate the specimen. This is a method of examining toxicity.
【0004】ところで、薬剤の毒性の評価としては、生
存細胞の数をカウントすることが、最も重要な検査法で
あるが、上述のベルらの方法は、コラ−ゲンマトリック
スに表皮細胞と線維芽細胞とを一緒に培養して検体の毒
性試験を行うため組織切片の状態を観察することはでき
るが、毒性の評価として重要な生存細胞の数をカウント
することは不可能であった。By the way, the most important test method for evaluating the toxicity of a drug is to count the number of viable cells, but the method of Bell et al., Mentioned above, uses epidermal cells and fibroblasts in a collagen matrix. Although it is possible to observe the condition of the tissue section for culturing the cells together with the cells for toxicity test of the specimen, it was impossible to count the number of viable cells, which is important for evaluation of toxicity.
【0005】[0005]
【発明が解決しようとする課題】本発明者らは、この欠
点を改良し、生存細胞の数をカウントすべく種々検討し
た結果、コラ−ゲンをマトリックスとし、表皮細胞と線
維芽細胞をそれぞれ別個にマトリックスで培養し、その
培養マトリックスを培地と空気の界面に固定後検体をの
せ、一定期間培養した後に、それぞれのマトリックス中
の生存細胞数及び組織切片を観察することにより細胞毒
性を評価出来ることを見出し、本発明を完成したもの
で、本発明の目的は、皮膚組織に対する検体の毒性を試
験する細胞毒性試験方法を提供するのである。DISCLOSURE OF THE INVENTION As a result of various studies to improve this drawback and count the number of viable cells, the present inventors have found that collagen is used as a matrix and epidermal cells and fibroblasts are separated from each other. It is possible to evaluate cytotoxicity by culturing cells in a matrix, fixing the culture matrix to the interface between the medium and air, placing a sample, and culturing for a certain period of time, and then observing the number of viable cells and tissue sections in each matrix. The present invention has been completed and the present invention has been completed, and an object of the present invention is to provide a cytotoxicity test method for testing the toxicity of a specimen to skin tissue.
【0006】[0006]
【課題を解決するための手段】本発明の要旨は、コラ−
ゲンスポンジ中にコラ−ゲンゲルを充填したマトリック
スに線維芽細胞と、表皮細胞をそれぞれ別個に培養した
後、その培養マトリックスを培地と空気の界面に固定
し、該培養マトリックス上に検体をのせてその細胞毒性
を評価する細胞毒性試験方法であり、細胞毒性を評価す
る方法として、培養マトリックス中の生存細胞数、およ
び組織切片によって細胞評価を行うのである。The gist of the present invention is to
After fibroblasts and epidermal cells were separately cultured in a matrix filled with collagen gel in Gensponge, the culture matrix was fixed at the interface between the medium and air, and the specimen was placed on the culture matrix to This is a cytotoxicity test method for evaluating cytotoxicity. As a method for evaluating cytotoxicity, cell evaluation is performed by the number of living cells in a culture matrix and a tissue section.
【0007】すなわち、本発明は、マトリックスに線維
芽細胞と、表皮細胞をそれぞれ別個に培養して複合培養
真皮細胞及び複合培養表皮細胞を形成し、これに検体を
のせて一定時間経過後、生存細胞数をカウントし、同時
に組織切片を観察するのである。That is, according to the present invention, fibroblasts and epidermal cells are separately cultured in a matrix to form a composite cultured dermal cell and a composite cultured epidermal cell. The number of cells is counted, and at the same time, the tissue section is observed.
【0008】以下に本発明を詳細に説明する。本発明の
培養皮膚用マトリックスは、例えば、以下に述べる方法
により作製することができる。The present invention will be described in detail below. The cultured skin matrix of the present invention can be produced, for example, by the method described below.
【0009】先ず、コラ−ゲンを周知の方法により酵素
処理して抗原性の少ないアテロコラ−ゲンを調製し、次
にアテロコラ−ゲンの水溶液を調製し、その粘度が上が
る様pHを調製したのちに、ホモジナイザ−によりクリ
−ム状の溶液とする。次いで、予め底面にアテロコラ−
ゲン水溶液を塗布して風乾し、薄膜をコ−トした容器に
上記クリ−ム状溶液を薄膜状に流し込み、アルカリ性雰
囲気下で静置して気泡を含んだ状態でゲル化させた後、
急速凍結させ真空乾燥して厚さ1〜2mm程度のコラ−
ゲンスポンジを骨格とするシ−トを作製する。First, collagen is enzymatically treated by a well-known method to prepare atelocollagen having less antigenicity, then an aqueous solution of atelocollagen is prepared, and then pH is adjusted so as to increase its viscosity. Using a homogenizer, make a cream solution. Next, in advance on the bottom
Gen solution was applied and air-dried, and the above-mentioned cream-like solution was poured into a thin film-coated container in a thin film form, and allowed to stand in an alkaline atmosphere to cause gelation in the state of containing bubbles,
A quick-freeze, vacuum-dried filter with a thickness of 1 to 2 mm.
A sheet having Gensponge as a skeleton is prepared.
【0010】上記シ−トの両面にそれぞれ紫外線を照射
して部分的に分子間架橋を導入した後、エチレンオキシ
ドガスにより滅菌する。次に組織培養タイプのアテロコ
ラ−ゲンを含む中性溶液を含浸させ、インキュベ−タ中
に静置してゲル化(コラ−ゲン分子の集合による繊維形
成)させることにより、本発明において使用するマトリ
ックスを作製する。Both surfaces of the sheet are irradiated with ultraviolet rays to partially introduce intermolecular crosslinks, and then sterilized with ethylene oxide gas. Next, a matrix used in the present invention is obtained by impregnating a neutral solution containing a tissue culture type atelocollagen and allowing it to stand in an incubator for gelation (fiber formation by aggregation of collagen molecules). To make.
【0011】次に、上記マトリックスに真皮細胞の線維
芽細胞、および、表皮細胞をそれぞれ播種し、血清を含
む培地で培養を行なう。この際、線維芽細胞はマトリッ
クスのゲル内に入った状態となる。Then, dermal fibroblasts and epidermal cells are seeded on the above matrix and cultured in a medium containing serum. At this time, the fibroblasts are in a state of entering the matrix gel.
【0012】線維芽細胞の培養マトリックスでは線維芽
細胞が直接空気に触れて損傷を受ける危険性を避けるた
めに、培養マトリックスを裏返しにしてマトリックスの
裏面が培地と空気の界面になるように置き、この上に細
胞毒性を評価する検体をのせる。一方表皮細胞の培養マ
トリックスでは重層化した表皮細胞が空気に触れること
により角化が促進されるため、表皮細胞層を空気に接す
るようにして、この上に細胞毒性を評価する検体をのせ
る。このマトリックスをシャ−レ底より数ミリ上方にあ
るステレス網上にのせる。この様にした後、毒性を評価
する薬剤などをガ−ゼなどに添加し、先の培養マトリッ
クス上面に乗せた。そして一定期間培養後、一部をコラ
ゲナ−ゼを用いマトリックスを溶かし生存細胞のみを染
色し、その細胞数を測定する。また一部をホルマリンな
どで固定して組織切片を作製後、その組織学的評価を行
なう。次に、実施例をもって更に本発明を具体的に説明
する。In the culture matrix of fibroblasts, in order to avoid the risk that the fibroblasts are directly exposed to air and damaged, the culture matrix is turned upside down so that the back surface of the matrix is the interface between the medium and air. A sample for evaluating cytotoxicity is placed on this. On the other hand, in the epidermal cell culture matrix, keratinization is promoted by the contact of the stratified epidermal cells with air, so that the epidermal cell layer is brought into contact with air and a sample for evaluating cytotoxicity is placed thereon. This matrix is placed on a stainless steel net several millimeters above the bottom of the dish. After this, a drug for evaluating toxicity was added to gase and the like and placed on the upper surface of the culture matrix. Then, after culturing for a certain period of time, a part of the matrix is dissolved using collagenase, only viable cells are stained, and the number of cells is measured. In addition, a part of the tissue is fixed with formalin or the like to prepare a tissue section, which is then evaluated histologically. Next, the present invention will be described more specifically with reference to Examples.
【0013】[0013]
実施例1 培養皮膚用マトリックスの作製:牛皮由来のコラ−ゲン
を酵素処理して調製したアテロコラ−ゲン(高研社製)
の1%水溶液をpH4に調製し、ホモジナイザ−で15
000rpmで3分間撹拌してクリ−ム状とした。予め
0.5%のアテロコラ−ゲン水溶液(pH4)0.5m
lを底面に塗布して風乾させたポリスチレン容器(6c
m×9.5cm)に、上記クリ−ム状の溶液15mlを
流し込みアンモニア雰囲気下に1時間静置してゲル化さ
せた。次いで充分に水洗した後、−70℃で急速凍結さ
せ真空乾燥してシ−ト状のスポンジを作製した。Example 1 Preparation of cultured skin matrix: Atelocollagen prepared by enzymatic treatment of cowhide-derived collagen (manufactured by Koken Co., Ltd.)
1% aqueous solution of was adjusted to pH 4 and homogenized with a homogenizer 15
The mixture was stirred at 000 rpm for 3 minutes to form a cream. 0.5m of 0.5% atelocollagen aqueous solution (pH 4) in advance
Polystyrene container (6c
15 ml of the above-mentioned cream-like solution was poured into (m × 9.5 cm) and allowed to stand for 1 hour in an ammonia atmosphere to cause gelation. Then, after thoroughly washing with water, it was rapidly frozen at -70 ° C and vacuum dried to prepare a sheet-like sponge.
【0014】15Wの紫外線ランプを用いて上記シ−ト
状スポンジの両面に15cmの距離で紫外線をそれぞれ
1時間ずつ照射して部分的に分子間架橋を導入した後、
直径0.5mmの貫通孔を4mm間隔で窄設した。つい
で、このシ−トをポリスチレン容器に入れ、エチレンオ
キシドガスにより滅菌し、Hank’s溶液(緩衝液)
で洗浄し気泡を除去した後、0.2%の組織培養用タイ
プIのアテロコラ−ゲン中性Hank’s溶液[高研社
CELLGEN(登録商標)]を2ml添加し、37℃
で2時間インキュベ−タ中に静置してゲル化させて、貫
通孔内及びシ−ト表面がゲル状アテロコラ−ゲンで被覆
された本発明の培養皮膚用マトリックスを得た。Both sides of the sheet-like sponge were irradiated with ultraviolet rays at a distance of 15 cm for 1 hour using a 15 W ultraviolet lamp to partially introduce intermolecular crosslinks,
Through holes having a diameter of 0.5 mm were provided at intervals of 4 mm. Then, this sheet was put into a polystyrene container, sterilized with ethylene oxide gas, and Hank's solution (buffer solution).
After washing with water to remove air bubbles, 2 ml of 0.2% type I telocoragen neutral Hank's solution for tissue culture [CELLGEN (trade name of Koken Co.)] was added, and the temperature was 37 ° C.
The mixture was allowed to stand in an incubator for 2 hours for gelation to obtain the cultured skin matrix of the present invention in which the inside of the through-hole and the surface of the sheet were coated with a gel-like atelocollagen.
【0015】植皮術の際に余剰となった皮膚細片をディ
スパ−ゼ処理により表皮と真皮に剥離して得られた真皮
をコラゲナ−ゼとヒアルロニダ−ゼの混合溶液で処理し
て線維芽細胞を採取し、10%ウシ胎児血清を含有する
Dulbecco’smodified Eagl
e’s Medium を培地として継代培養した。Fibroblasts are obtained by treating the dermis obtained by exfoliating the skin strips that have become excessive during skin grafting into the epidermis and dermis by treatment with disperse with a mixed solution of collagenase and hyaluronidase. Was collected and contained 10% fetal bovine serum in Dulbecco's modified Eagle.
Subculture was performed using e's Medium as a medium.
【0016】コラ−ゲンのマトリックス(10cm×1
8cm)上に継代培養した線維芽細胞を5×105 c
ells/cm2の密度で播種して1週間培養すること
により複合培養真皮を調製した。直径90mmの培養シ
ャ−レに高さ3mmのステンレス網を置き、この上に裁
断した複合培養真皮(4cm×4cm)を裏返しての
せ、この複合培養真皮が培地と空気の界面に位置するよ
うに培地を25ml添加した。Collagen matrix (10 cm x 1
8 cm) subcultured fibroblasts to 5 × 10 5 c
The composite dermis was prepared by seeding at a density of ells / cm 2 and culturing for 1 week. A stainless mesh with a height of 3 mm is placed on a culture dish with a diameter of 90 mm, and the cut composite culture dermis (4 cm x 4 cm) is turned upside down on the mesh so that the composite culture dermis is located at the interface between the medium and air. 25 ml of medium was added.
【0017】このような状態で、複合培養真皮の上に抗
菌剤含有軟膏塗布ガ−ゼ(4cm×4cm)あるいは抗
菌剤含有被覆材(4cm×4cm)をのせて、37℃の
インキュベ−タ−内に4日間静置した。その後、複合培
養真皮を3cm×3cmの大きさに切り取り、5mlの
0.5%コラゲナ−ゼ溶液に入れ37℃で30分間静置
した後、撹拌して細胞浮遊液を調製してトリパンブル−
で染色した後、血球計算板を用いて生存細胞数を測定し
た。また、複合培養真皮の一部を10%ホルマリンで固
定して組織標本を作製し、ヘマトキシリン・エオジン染
色して組織学的検討を行った。In this state, an antibacterial agent-containing ointment coating gauze (4 cm × 4 cm) or an antibacterial agent-containing coating material (4 cm × 4 cm) was placed on the complex cultured dermis, and the incubator at 37 ° C. It was left to stand for 4 days. After that, the composite cultured dermis was cut into a size of 3 cm × 3 cm, placed in 5 ml of 0.5% collagenase solution and allowed to stand at 37 ° C. for 30 minutes, and then stirred to prepare a cell suspension and trypan bleed.
After staining with, the number of viable cells was measured using a hemocytometer. Further, a part of the composite cultured dermis was fixed with 10% formalin to prepare a tissue sample, which was stained with hematoxylin / eosin for histological examination.
【0018】植皮術の際に余剰となった皮膚細片をディ
スパ−ゼ処理により表皮と真皮に剥離して得られた表皮
をトリプシン処理して表皮細胞を採取し、Greenの
方法に準じて3T3 feeder layer の存
在下で表皮細胞を培養した。コラ−ゲンのマトリックス
(10cm×18cm)上に表皮細胞を5×105ce
lls/cm2の密度で播種して1週間培養することに
より複合培養表皮を調製した。上述と同様に、複合培養
表皮を培地と空気の界面に置き、この上に抗菌剤含有軟
膏塗布ガ−ゼあるいは抗菌剤含有被覆材をのせ、37℃
のインキュベ−タ−内に4日間静置した。その後、上述
と同様に、細胞浮遊液を調製して生存細胞数を測定し
た。また、ヘマトキシリン・エオジン染色して組織学的
検討を行った。Excessive skin debris during skin grafting was separated into epidermis and dermis by disperse treatment, and the resulting epidermis was trypsinized to collect epidermal cells, and 3T3 was prepared according to Green's method. Epidermal cells were cultured in the presence of feeder layer. 5 × 10 5 cells of epidermal cells were placed on a collagen matrix (10 cm × 18 cm).
A composite culture epidermis was prepared by seeding at a density of 11s / cm 2 and culturing for 1 week. Similarly to the above, the composite culture epidermis is placed on the interface between the medium and the air, and an antibacterial agent-containing ointment coating gauze or an antibacterial agent-containing covering material is placed thereon, and the temperature is 37 ° C
It was allowed to stand in the incubator for 4 days. Then, a cell suspension was prepared and the number of viable cells was measured in the same manner as described above. In addition, hematoxylin / eosin staining was carried out for histological examination.
【0019】検体として、最近上市されたスルファジア
ジン銀含有被覆材を使用し、上述の複合培養真皮に被覆
材を乗せ、培養3日後に生存細胞数をカウントしたとこ
ろ、約40%であり、同量のスルファジアジン銀含有ク
リ−ムを塗布したガ−ゼを検体とすると、生存細胞数は
0%となった。As a sample, a coating material containing silver sulfadiazine, which was recently put on the market, was used, the coating material was placed on the above-mentioned complex cultured dermis, and the number of viable cells was counted after 3 days of culture, and it was about 40%. The number of viable cells was 0% when the sample coated with the cream containing silver sulfadiazine was used as a sample.
【0020】複合培養表皮は、コラ−ゲンマトリックス
の表面に表皮細胞が3〜4層に重層化しており、この上
に直接検体をのせるので検体から放出される薬剤が直接
表皮細胞に影響を及ぼす。上述のスルファジアジン銀含
有被覆材を検体とすると、培養3日後には、生存細胞数
は約50%であり、同量のスルファジアジン銀含有クリ
−ムを塗布したガ−ゼを検体とすると、生存細胞数は0
%であった。In the composite culture epidermis, epidermal cells are layered in 3 to 4 layers on the surface of the collagen matrix, and the specimen is directly placed on the epidermal cells, so that the drug released from the specimen directly affects the epidermal cells. Exert. When the above-mentioned coating material containing silver sulfadiazine is used as a specimen, the number of viable cells is about 50% after 3 days of culturing, and when a sample coated with the same amount of cream containing silver sulfadiazine is used as a specimen, viable cells are used. Number is 0
%Met.
【0021】[0021]
【発明の効果】以上述べたように、本発明では、皮膚組
織に類似した複合培養表皮及び複合培養真皮を使用し、
これに検体をのせて生存細胞数を測定するのであるから
従来の方法に比して遥かに精度高く検体の細胞に対する
毒性を知ることが出来る。As described above, according to the present invention, the combined culture epidermis and the combined culture dermis similar to the skin tissue are used,
Since the number of surviving cells is measured by placing a sample on this, it is possible to know the toxicity of the sample to the cells with much higher accuracy than in conventional methods.
Claims (2)
を充填したマトリックスに線維芽細胞と、表皮細胞をそ
れぞれ別個に培養後、その培養マトリックスを培地と空
気の界面に固定し、該培養マトリックス上に検体をのせ
てその細胞毒性を評価する細胞毒性試験方法。1. A culture medium in which fibroblasts and epidermal cells are separately cultured in a matrix in which collagen gel is filled in collagen sponge, and the culture matrix is fixed on the interface between a medium and air. A cytotoxicity test method in which a sample is placed on and the cytotoxicity is evaluated.
び組織切片によって細胞評価を行う請求項第1項記載の
細胞毒性試験の方法。2. The method of the cytotoxicity test according to claim 1, wherein the cell evaluation is performed by the number of viable cells in the culture matrix and the tissue section.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4153692A JPH05336996A (en) | 1992-06-12 | 1992-06-12 | Method for testing cytotoxicity with cultured cell |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4153692A JPH05336996A (en) | 1992-06-12 | 1992-06-12 | Method for testing cytotoxicity with cultured cell |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH05336996A true JPH05336996A (en) | 1993-12-21 |
Family
ID=15568054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4153692A Pending JPH05336996A (en) | 1992-06-12 | 1992-06-12 | Method for testing cytotoxicity with cultured cell |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH05336996A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018216A1 (en) * | 1993-12-30 | 1995-07-06 | Nitta Gelatin Inc. | Process for embedding culture of animal cells |
US6132979A (en) * | 1997-05-27 | 2000-10-17 | Nec Corporation | Cytotoxicity testing method |
WO2005080977A1 (en) * | 2004-02-24 | 2005-09-01 | Rohto Pharmaceutical Co., Ltd. | Method of estimating skin irritation |
WO2016031971A1 (en) * | 2014-08-29 | 2016-03-03 | 日立化成株式会社 | Cell trapping method, method for producing specific cell-trapping device, and method for producing specific cell-containing solution |
-
1992
- 1992-06-12 JP JP4153692A patent/JPH05336996A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018216A1 (en) * | 1993-12-30 | 1995-07-06 | Nitta Gelatin Inc. | Process for embedding culture of animal cells |
US5712161A (en) * | 1993-12-30 | 1998-01-27 | Nitta Gelatin Inc. | Method for culturing animal cells in collagen drops on a support |
US6132979A (en) * | 1997-05-27 | 2000-10-17 | Nec Corporation | Cytotoxicity testing method |
WO2005080977A1 (en) * | 2004-02-24 | 2005-09-01 | Rohto Pharmaceutical Co., Ltd. | Method of estimating skin irritation |
WO2016031971A1 (en) * | 2014-08-29 | 2016-03-03 | 日立化成株式会社 | Cell trapping method, method for producing specific cell-trapping device, and method for producing specific cell-containing solution |
JPWO2016031971A1 (en) * | 2014-08-29 | 2017-06-08 | 日立化成株式会社 | Cell capture method, method for producing specific cell-captured device, and method for producing specific cell-containing solution |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8222031B2 (en) | Three-dimensional skin model | |
Wang et al. | Novel biodegradable porous scaffold applied to skin regeneration | |
JP2858087B2 (en) | Tissue culture substrate and tissue culture method | |
EP1778307B1 (en) | Cross-linked collagen matrix for producing a skin equivalent | |
CN107988158B (en) | Three-dimensional tumor model acellular porous scaffold, construction method and application thereof | |
JPH05506169A (en) | Synthetic biological skin equivalent | |
CN101489395A (en) | Oral tissue regeneration and repair | |
DE69530409T2 (en) | BIOMATERIAL CONTAINING EPITHELIC CELLS AND THEIR USE AS A TRANSPLANT | |
US5980888A (en) | Keratinocytes attached to microcarriers for treatment of skin wounds | |
WO2007090575A1 (en) | Skin model with dendritic cells | |
JP3951148B2 (en) | Artificial skin containing skin appendage-like structure and method for producing the same | |
Howlett et al. | Epithelial-stromal interactions in the adult bladder: Urothelial growth, differentiation, and maturation on culture fascsimiles of bladder stroma | |
JPH1147258A (en) | Medical base material containing gelatin and collagen | |
JPH05336996A (en) | Method for testing cytotoxicity with cultured cell | |
CN105801920B (en) | Chemically cross-linking composition, biomedical materials containing same and uses thereof | |
CN109722410B (en) | 3D full-layer skin model, culture medium for forming same and preparation method | |
Duong et al. | Assessment of morphological and immunohistological alterations in long-term keloid skin explants | |
WO2007061205A1 (en) | Culture method of fibroblast using placenta extract and composition for skin regeneration using the same | |
JPH08163996A (en) | Testing method of toxicity of animal tissue | |
BR112013030828B1 (en) | PROCESS TO PREPARE A HAIRY LEATHER EQUIVALENT | |
EP1500697B1 (en) | Bioartificial, primarily vascularized tissue for pharmaceutical tests, method for its production, use of it in a bioreactor. | |
JP7083866B2 (en) | Skin model | |
CN103041453A (en) | Double-layer skin covering material compositely built by collagen/fibrin glue-VEGF (vascular endothelial growth factor) and mesenchymal stem cell as well as preparation method and application of double-layer skin covering material | |
CN111117945B (en) | Skin model containing melanin, construction method and application thereof | |
KR20220087890A (en) | Dermal-based artificial skin comprising a basement membrane layer and method for manufacturing the same |